Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Novo’s Wegovy Nears Japan Approval as First MASH Therapy
Quick Look: An MHLW panel backed Wegovy as Japan’s first treatment for MASH, recommending its use in non-cirrhotic disease with moderate or advanced liver fibrosis. The session also supported three NMEs — Biogen’s diroximel fumarate, Santen’s netarsudil, and Sanofi’s rilzabrutinib…
To read the full story
Related Article
- Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
- Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
- Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
June 22, 2026
- Wegovy’s MASH Label Expansion and More Up for Japan Panel Review on May 29
May 18, 2026
- Sanofi Files ITP Drug Rilzabrutinib in Japan
October 6, 2025
- Chugai Seeks Avastin Label Expansion for Neurofibromatosis Type 2
September 25, 2025
- Novo Japan Files Sogroya for SGA-Related and Noonan Syndrome Short Stature
July 31, 2025
- Santen Files Glaucoma Drug Rhopressa in Japan
July 31, 2025
REGULATORY
- Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
- Repatha Optimal Use Guidelines to Be Simplified
October 1, 2026
- Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
September 30, 2026
- MHLW Panel Backs Easing Protopic Contraindication for Young Children
September 30, 2026
- PMDA Flags New Safety Risks with 3 Drugs
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…